title: Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
abstract: T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B-cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B-cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.
authors.affiliation: Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10032, USA. oo2130@columbia.edu
authors.forename: Owen A
authors.initials: OA
authors.lastname: O'Connor
authors.forename: Paul A
authors.initials: PA
authors.lastname: Hamlin
authors.forename: Carol
authors.initials: C
authors.lastname: Portlock
authors.forename: Craig H
authors.initials: CH
authors.lastname: Moskowitz
authors.forename: Ariela
authors.initials: A
authors.lastname: Noy
authors.forename: David J
authors.initials: DJ
authors.lastname: Straus
authors.forename: Barbara
authors.initials: B
authors.lastname: Macgregor-Cortelli
authors.forename: Ellen
authors.initials: E
authors.lastname: Neylon
authors.forename: Debra
authors.initials: D
authors.lastname: Sarasohn
authors.forename: Otila
authors.initials: O
authors.lastname: Dumetrescu
authors.forename: Diane R
authors.initials: DR
authors.lastname: Mould
authors.forename: Martin
authors.initials: M
authors.lastname: Fleischer
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Zelenetz
authors.forename: Frank
authors.initials: F
authors.lastname: Sirotnak
authors.forename: Steven
authors.initials: S
authors.lastname: Horwitz
mesh_terms: D000328:Adult; D000368:Aged; D000630:Aminopterin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D005493:Folic Acid Antagonists / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D016399:Lymphoma, T-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D026901:Membrane Transport Proteins / Q000378:metabolism; D008875:Middle Aged; D049268:Positron-Emission Tomography; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: C418863:10-propargyl-10-deazaaminopterin; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D026901:Membrane Transport Proteins; C120043:SLC19A2 protein, human; D000630:Aminopterin